Biomedcode

Biomedcode is a CRO with extensive expertise in efficacy evaluation studies using standardized preclinical platforms of inflammatory and fibroproliferative diseases as well as cancer. Biomedcode combines scientific consultation and custom-tailored solutions towards optimizing the validation procedure of novel human therapeutics including biologics, biosimilars, biobetters and small molecules. Offered services include animal disease model development, in-vivo and ex-vivo preclinical drug evaluation, PK/PD analysis, standardized sample collection and analysis, histopathology, immunohistochemistry as well as molecular, cellular and immunological assays and pharmacogenomics. Since 2006, Biomedcode has provided its services to more than 126 pharmaceutical and biotech companies in Europe, the USA and Asia....

Novel humanized animal disease models of chronic inflammatory diseases,rheumatoid arthritis,crohn's crohn,multiple sclerosis,psoriasis,disease biomarkers identification through metabonomics,molecular pathways characterization through pharmacogenomics,cancer,eae,mouse models,preclinical testing,and drug development

Biomedcode operates in the Biotechnology research industry.

Biomedcode's revenue is 11m - 100m

Biomedcode has 11 - 50 employees.